LYEL vs PCAR · rev $6.0K vs P/E 25, rev $33.66B
Lyell Immunopharma Inc (LYEL) versus PACCAR Inc (PCAR) — a side-by-side from cached financials, not a winner call.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
PACCAR Inc (PCAR) is a farm & heavy construction machinery company listed on NASDAQ.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
Latest reported PCAR revenue for 2024-12-31 was $33.66B. Net income was $4.16B. Revenue was down 4.2% from 2023-12-31 to 2024-12-31. PCAR currently screens at market cap $61.75B and trailing P/E 25.0.
LYEL currently screens at market cap $143.5M. PCAR currently screens at market cap $61.75B and trailing P/E 25.0.
Not investment advice. Open the LYEL and PCAR stock pages for the full models.
Not investment advice.